X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs CIPLA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH CIPLA PANACEA BIOTECH/
CIPLA
 
P/E (TTM) x 80.9 44.7 181.1% View Chart
P/BV x 1.8 3.7 48.8% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 PANACEA BIOTECH   CIPLA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
CIPLA
Mar-17
PANACEA BIOTECH/
CIPLA
5-Yr Chart
Click to enlarge
High Rs149622 23.9%   
Low Rs82458 18.0%   
Sales per share (Unadj.) Rs84.1181.9 46.3%  
Earnings per share (Unadj.) Rs-18.312.9 -142.2%  
Cash flow per share (Unadj.) Rs-6.729.3 -22.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs83.7155.7 53.8%  
Shares outstanding (eoy) m61.25804.51 7.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.43.0 46.2%   
Avg P/E ratio x-6.342.0 -15.0%  
P/CF ratio (eoy) x-17.218.4 -93.6%  
Price / Book Value ratio x1.43.5 39.8%  
Dividend payout %015.5 0.0%   
Avg Mkt Cap Rs m7,074434,516 1.6%   
No. of employees `0002.823.0 11.9%   
Total wages/salary Rs m1,44926,338 5.5%   
Avg. sales/employee Rs Th1,874.16,349.1 29.5%   
Avg. wages/employee Rs Th527.01,143.0 46.1%   
Avg. net profit/employee Rs Th-407.7449.3 -90.7%   
INCOME DATA
Net Sales Rs m5,154146,302 3.5%  
Other income Rs m1002,287 4.4%   
Total revenues Rs m5,254148,589 3.5%   
Gross profit Rs m-76624,758 -3.1%  
Depreciation Rs m71113,229 5.4%   
Interest Rs m1,5031,594 94.3%   
Profit before tax Rs m-2,88112,222 -23.6%   
Minority Interest Rs m110-   
Prior Period Items Rs m-6-70 8.2%   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m171,798 0.9%   
Profit after tax Rs m-1,12110,354 -10.8%  
Gross profit margin %-14.916.9 -87.9%  
Effective tax rate %-0.614.7 -4.0%   
Net profit margin %-21.87.1 -307.4%  
BALANCE SHEET DATA
Current assets Rs m3,81087,370 4.4%   
Current liabilities Rs m8,36533,081 25.3%   
Net working cap to sales %-88.437.1 -238.2%  
Current ratio x0.52.6 17.2%  
Inventory Days Days15687 179.0%  
Debtors Days Days6762 107.9%  
Net fixed assets Rs m14,480111,567 13.0%   
Share capital Rs m611,609 3.8%   
"Free" reserves Rs m903123,645 0.7%   
Net worth Rs m5,127125,254 4.1%   
Long term debt Rs m5,83236,454 16.0%   
Total assets Rs m19,433209,532 9.3%  
Interest coverage x-0.98.7 -10.6%   
Debt to equity ratio x1.10.3 390.8%  
Sales to assets ratio x0.30.7 38.0%   
Return on assets %2.05.7 34.4%  
Return on equity %-21.98.3 -264.6%  
Return on capital %3.68.5 42.8%  
Exports to sales %24.534.2 71.7%   
Imports to sales %10.28.3 122.1%   
Exports (fob) Rs m1,26450,050 2.5%   
Imports (cif) Rs m52512,203 4.3%   
Fx inflow Rs m1,53951,066 3.0%   
Fx outflow Rs m94217,678 5.3%   
Net fx Rs m59733,388 1.8%   
CASH FLOW
From Operations Rs m59923,824 2.5%  
From Investments Rs m-438-13,127 3.3%  
From Financial Activity Rs m-303-13,239 2.3%  
Net Cashflow Rs m-141-2,478 5.7%  

Share Holding

Indian Promoters % 74.5 16.0 465.6%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.6 12.2 4.9%  
FIIs % 1.3 23.7 5.5%  
ADR/GDR % 0.0 1.1 -  
Free float % 23.6 26.2 90.1%  
Shareholders   10,259 161,166 6.4%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON LTD  FULFORD INDIA  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Aug 17, 2017 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - ALKEM LABORATORIES COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS